(0.16%) 5 477.90 points
(0.04%) 39 128 points
(0.49%) 17 805 points
(0.06%) $80.88
(-5.04%) $2.62
(-0.91%) $2 309.70
(-0.37%) $28.76
(2.85%) $1 014.50
(0.33%) $0.936
(0.73%) $10.68
(0.50%) $0.792
(0.85%) $88.23
-42.97% $ 0.0722
Live Chart Being Loaded With Signals
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders...
Stats | |
---|---|
Volumen de hoy | 4.59M |
Volumen promedio | 446 108 |
Capitalización de mercado | 1.04M |
EPS | $-1.160 ( Q1 | 2023-05-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0427 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0750 (443.79%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-04-21 | Sensenig Bethany | Sell | 9 100 | Common stock |
2023-03-29 | Sirgo Mark A | Buy | 7 885 | Common Stock |
2023-03-29 | Rice Yehuda Michael | Buy | 7 885 | Common Stock |
2023-03-29 | Johnson Lorin K | Buy | 7 885 | Common Stock |
2023-03-29 | Constantino Michael T. | Buy | 7 885 | Common Stock |
INSIDER POWER |
---|
92.63 |
Last 98 transactions |
Buy: 58 384 829 | Sell: 18 657 625 |
Volumen Correlación
9 Meters Biopharma Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
VRAY | 0.878 |
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
9 Meters Biopharma Inc Correlación - Moneda/Commodity
9 Meters Biopharma Inc Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $0 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-3.51 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-3.03 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
9 Meters Biopharma Inc
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico